Researching AXIUM Coiling Experience and Recanalization (RACER) (RACER)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00703794
Recruitment Status : Completed
First Posted : June 24, 2008
Last Update Posted : September 29, 2017
Information provided by (Responsible Party):
Medtronic Neurovascular Clinical Affairs

June 23, 2008
June 24, 2008
September 29, 2017
June 2008
July 2010   (Final data collection date for primary outcome measure)
Percent Occlusion [ Time Frame: Defined in protocol ]
Same as current
Complete list of historical versions of study NCT00703794 on Archive Site
Morbidity/Mortality [ Time Frame: Defined in protocol ]
Same as current
Not Provided
Not Provided
Researching AXIUM Coiling Experience and Recanalization (RACER)
ev3 Researching AXIUM Coiling Experience and Recanalization (RACER)

The data collected in this study will be used to support International Regulatory submissions. The study objective is to evaluate the continued safety and efficacy of the AXIUM Progressive Coil System.

This Device has been used clinically at approximately 150 Institutions under FDA 510(k) clearance since April 24, 2007. The device received CE authorization on June 30, 2007. Through December 2007, more than 1000 patients have been treated with the AXIUM Coils.

Not Provided
Observational [Patient Registry]
Observational Model: Other
Time Perspective: Prospective
6 Months
Not Provided
Probability Sample
Patients with intracranial aneurysm, either ruptured or un-ruptured, with aneurysm has a maximum diameter of 2mm to 20mm
  • Aneurysms
  • Vascular Diseases
  • Cerebrovascular Disorders
  • Intracranial Arterial Diseases
Device: The AXIUM Progressive Coil System
Embolization of aneurysm
Intervention: Device: The AXIUM Progressive Coil System

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
December 2011
July 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patient or patient's legally authorized representative has signed and dated an Informed Consent Form
  • Must be at least 18 years of age
  • Aneurysm location, angio-architecture, morphology, or medical condition, is considered by the neurosurgical / interventional team to be at very high risk for management by traditional operative techniques, or aneurysm is considered to be inoperable
  • Patient is willing to conduct follow-up visits

Exclusion Criteria:

  • Aneurysm was previously treated
  • Patient has a cerebral aneurysm with a location, angioarchitecture or morphology that presents an unacceptable risk of morbidity due to the Study procedures
  • Patient is participating in another clinical research Study
  • Patient has a medical, social or psychological condition, which precludes the patient from receiving Study required treatment, evaluation, procedures and follow-up
  • Female patient is pregnant or breast-feeding
Sexes Eligible for Study: All
18 Years and older   (Adult, Older Adult)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Medtronic Neurovascular Clinical Affairs
Medtronic Neurovascular Clinical Affairs
Not Provided
Principal Investigator: Ajay K Wakhloo, MD, PhD University of Massachusetts, Worcester
Medtronic Neurovascular Clinical Affairs
September 2017